1,286 followers
RT @ConradEnge98050: $CRVS starting trial P1b/2 in renal cell cancer has also shown efficacy in models for other solid tumors w/ reductions…
555 followers
$CRVS starting trial P1b/2 in renal cell cancer has also shown efficacy in models for other solid tumors w/ reductions in tumor size particularly for: - colon cancer ($16B market) - kidney (RCC) ($6.5B) - melanoma ($5.5B growing 10%/yr) #soquelitinib rever
27 followers
RT @FrontImmunol: New Research: Different evasion strategies in multiple myeloma: Multiple myeloma is the second most common malignant hema…
312 followers
RT @FrontImmunol: New Research: Different evasion strategies in multiple myeloma: Multiple myeloma is the second most common malignant hema…